SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 20, 2017
|
PROTAGENIC THERAPEUTICS, INC. |
|
(Exact name of Company as specified in its charter) |
|
Delaware |
|
000-51353 |
|
06-1390025 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
149 Fifth Avenue, Suite 500, New York, NY |
|
10010 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
212-994-8200 |
|
|
|
(Company’s telephone number, including area code) |
|
|
|
|
|
|
(Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 20, 2017, Gregory K. Ekizian, a director of Protagenic Therapeutics, Inc. (the “Company”) and the Chairman of the Audit Committee of the Company’s Board of Directors (the “Board”), notified the Company that he was resigning from the Board effective immediately. Mr. Ekizian’s resignation is due to compliance with restrictions imposed upon him by a new position he has taken with an unrelated company. Accordingly, Mr. Ekizian will not stand for re-election to the Board at the Company’s upcoming Annual Meeting of Stockholders, which is currently scheduled to be held on July 7, 2017 at 11:00 a.m., Eastern Daylight Time, at the Company’s offices in New York City. The Company plans to appoint a replacement for the position vacated by Mr. Ekizian in the near future.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PROTAGENIC THERAPEUTICS, INC. |
| |
|
|
|
|
| |
|
Date: June 23, 2017 |
By: |
/s/ | Alexander K. Arrow |
|
|
|
|
Name: Alexander K. Arrow |
| |
|
|
|
Title: Chief Financial Officer |
| |
3